Effects of Pro12Ala polymorphism of peroxisome proliferator‐activated receptor γ2 gene on rosiglitazone response in type 2 diabetes

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical pharmacology and therapy

• Publication date

  2005-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.clpt.2005.04.013PMID 16084854
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus.

  2005cited by this paper
• Limitation of the validity of the homeostasis model assessment as an index of insulin resistance in Korea.

  2005cited by this paper
• The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes.

  2005cited by this paper
• Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study.

  2004cited by this paper
• Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes.

  2003cited by this paper
• No influence of the PPARgamma2 Pro12Ala genotype on serum adiponectin concentrations in healthy Europeans.

  2003cited by this paper
• A functional variant in the peroxisome proliferator-activated receptor gamma2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians.

  2003cited by this paper
• Analysis of the Relationship Between the Pro12Ala Variant in the PPAR-γ2 Gene and the Response Rate to Therapy With Pioglitazone in Patients With Type 2 Diabetes

  2003cited by this paper
• The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism.

  2002cited by this paper
• The Peroxisome Proliferator-Activated Receptor-γ2 Pro12Ala Polymorphism

  2002cited by this paper
• Effect of the Pro12Ala polymorphism of the PPAR-gamma2 gene on long-term weight change in Finnish non-diabetic subjects.

  2001cited by this paper
• Mutations of the peroxisome proliferator-activated receptor γ (PPARγ) gene in a Japanese population : the Pro12Ala mutation in PPARγ2 is associated with lower concentrations of serum total and non-HDL cholesterol

  2001cited by this paper
• Mutations of the peroxisome proliferator-activated receptor gamma (PPAR gamma) gene in a Japanese population : the Pro12Ala mutation in PPAR gamma 2 is associated with lower concentrations of serum total and non-HDL cholesterol.

  2001cited by this paper
• The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes.

  2001cited by this paper
• Genetic variation in the peroxisome proliferator-activated receptor-gamma2 gene (Pro12Ala) affects metabolic responses to weight loss and subsequent weight regain.

  2001cited by this paper
• Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects.

  2000cited by this paper
• The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes.

  2000cited by this paper
• The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes

  2000cited by this paper
• Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis.

  2000cited by this paper
• The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes

  2000cited by this paper
• Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women.

  1999cited by this paper
• PPARγ, the ultimate thrifty gene

  1999cited by this paper
• PPARgamma, the ultimate thrifty gene.

  1999cited by this paper
• Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation

  1998cited by this paper
• A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity

  1998cited by this paper
• Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations.

  1998cited by this paper
• Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes.

  1998cited by this paper
• Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene.

  1997cited by this paper
• Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation.

  1997cited by this paper
• The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene*

  1997cited by this paper
• Molecular Scanning of the Human Peroxisome Proliferator Activated Receptor γ (hPPARγ) Gene in Diabetic Caucasians: Identification of a Pro12Ala PPARγ2 Missense Mutation

  1997cited by this paper
• Effects of Troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy

  1996cited by this paper
• Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes

  1996cited by this paper
• An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*)

  1995cited by this paper
• An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).

  1995cited by this paper
• The Pima Indians

  1975cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper

• Harnessing Pharmacomultiomics for Precision Medicine in Diabetes: A Comprehensive Review

  2025cites this paper
• Pharmacogenomics and Personalized Medicine

  2024cites this paper
• Updates of precision medicine in type 2 diabetes

  2023cites this paper
• Correlation between PPARG Pro12Ala Polymorphism and Therapeutic Responses to Thiazolidinediones in Patients with Type 2 Diabetes: A Meta-Analysis

  2023cites this paper
• Interactions between diabetic and hypertensive drugs: a pharmacogenetics approach

  2023cites this paper
• Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice

  2021cites this paper
• PGPM_A_329787 1441..1455

  2021cites this paper
• Quantile-Dependent Heritability of Glucose, Insulin, Proinsulin, Insulin Resistance, and Glycated Hemoglobin

  2021cites this paper
• PPARG genindeki Pro12Ala polimorfizmi, Türk populasyonunda insülin direnci ve tip 2 diyabet ile ilişkili değildir: Bir vaka-kontrol çalışması

  2021cites this paper
• Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?

  2021cites this paper
• PPARγ and Diabetes: Beyond the Genome and Towards Personalized Medicine

  2021cites this paper
• Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2020cites this paper
• Фармакогенетические аспекты в терапии сахарного диабета 2-го типа

  2020cites this paper
• Diabetes and Genetics: A Relationship Between Genetic Risk Alleles, Clinical Phenotypes and Therapeutic Approaches.

  2020cites this paper
• Pharmacogenetic Aspects of Type 2 Diabetes Treatment

  2020cites this paper
• Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2020cites this paper
• Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: A cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank

  2020cites this paper
• Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine

  2019cites this paper
• Frequency of CYP2C9 (*2, *3 and IVS8-109A>T) allelic variants, and their clinical implications, among Mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin

  2019cites this paper
• Diabetes: Is There a Future for Pharmacogenomics Guided Treatment?

  2019cites this paper
• The Importance of Precision Medicine in Type 2 Diabetes Mellitus (T2DM): From Pharmacogenetic and Pharmacoepigenetic Aspects.

  2019cites this paper
• Precision medicine in diabetes prevention, classification and management

  2018cites this paper
• Although ABCC 8 1369 Ala and KCNJ 11 23 K variants

  2018cites this paper
• Advances on PPARγ Research in the Emerging Era of Precision Medicine.

  2018cites this paper
• Pharmacogenetics and target identification in diabetes.

  2018cites this paper
• 22 Pharmacogenetics for T 2 DM and Anti-Diabetic Drugs

  2017cites this paper
• Introduction: Every Individual Is Different and Precision Medicine Offers Options for Disease Control and Treatment

  2017cites this paper
• Trends and challenges in managing diabetes mellitus-personalized medicine

  2017cites this paper
• Using Personalized Medicine in the Management of Diabetes Mellitus

  2017cites this paper
• Pharmacogenomics of Type 2 Diabetes Mellitus

  2017cites this paper
• Targeting endothelial metaflammation to counteract diabesity cardiovascular risk: Current and perspective therapeutic options

  2017cites this paper
• [Pharmacogenetics of oral antidiabetic treatment].

  2016cites this paper
• Pharmacogenetic studies update in type 2 diabetes mellitus.

  2016cites this paper
• Personalized Therapy by Phenotype and Genotype

  2016cites this paper
• Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents

  2016cites this paper
• A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes

  2016cites this paper
• Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers.

  2016cites this paper
• Ризики лапароскопічної холецистектомії у хворих на жовчнокам’яну хворобу на тлі ішемічної хвороби серця

  2016cites this paper
• Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery

  2016cites this paper
• Pharmacogenetics and personalized treatment of type 2 diabetes mellitus

  2016cites this paper
• Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs

  2016cites this paper
• Genetics of Drug Response in Type 2 Diabetes

  2015cites this paper
• Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?

  2015cites this paper
• Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies?

  2015cites this paper
• Personalized medicine in diabetes mellitus: current opportunities and future prospects

  2015cites this paper
• Genetics of Type 2 Diabetes: Insights into the Pathogenesis and Its Clinical Application

  2014cites this paper
• Genetic variants associated with response to oral antihyperglycemic agents metformin

  2014influential citation
• Leveraging cross-species transcription factor binding site patterns: from diabetes risk loci to disease mechanisms.

  2014cites this paper
• Patient profiling in diabetes and role of canagliflozin

  2014influential citation
• Pharmacogenomics of Oral Antidiabetic Drugs

  2014cites this paper
• The Pharmacogenetics of Type 2 Diabetes: A Systematic Review

  2014cites this paper
• Impact of GNB3-C825T, ADRB3-Trp64Arg, UCP2-3′UTR 45 bp del/ins, and PPARγ-Pro12Ala Polymorphisms on Bofutsushosan Response in Obese Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial

  2014cites this paper
• Personalized medicine in Type 2 Diabetes

  2014cites this paper
• The Role of Pharmacogenetics in Drug Disposition and Response of Oral Glucose-Lowering Drugs

  2013cites this paper
• The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPAR&ggr; on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes

  2013cites this paper
• The genetics of type 2 diabetes and its clinical relevance

  2013cites this paper
• Pharmacogenetics and personalized treatment of type 2 diabetes

  2013cites this paper
• Current clinical evidence on pioglitazone pharmacogenomics

  2013influential citation
• Pharmacogenetics of Oral Antidiabetic Drugs

  2013cites this paper
• Discovery of DiPeptidyl Peptidase-4 Gene Variants and the Associations with Efficacy of Vildagliptin in Patients with Type 2 Diabetes - A Pilot Study

  2013cites this paper
• Individualized Therapy for Type 2 Diabetes

  2012cites this paper
• Genetics of type 2 diabetes mellitus and other specific types of diabetes; its role in treatment modalities.

  2012cites this paper
• Association of the PPARG Pro12Ala polymorphism with type 2 diabetes and incident coronary heart disease in a Hong Kong Chinese population.

  2012cites this paper
• PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China

  2012cites this paper
• Pharmacogenetics of Glucose-Lowering Drug Treatment

  2012cites this paper
• Pharmacogenetics of Oral Antidiabetic Drugs: Potential Clinical Application

  2012cites this paper
• Type 2 diabetes in pediatrics and adults: thoughts from a clinical pharmacology perspective.

  2012cites this paper
• Exercise training, genetics and type 2 diabetes‐related phenotypes

  2012cites this paper
• Investigation of the relationship between genetic and environmental risk factors associated with obesity and insulin resistance in South African patients with non-alcoholic fatty liver disease (NAFLD)

  2012cites this paper
• Clinical Implications of Pharmacogenetic Data

  2012cites this paper
• Effects of KCNQ1 Polymorphisms on the Therapeutic Efficacy of Oral Antidiabetic Drugs in Chinese Patients With Type 2 Diabetes

  2011cites this paper
• Effects of peroxisome proliferator activated receptor-gamma 2 gene Pro12Ala polymorphism on fasting blood lipids: a meta-analysis.

  2011cites this paper
• Polymorphism of adiponectin (45T/G) and adiponectin receptor-2 (795G/A) in an Iranian population: relation with insulin resistance and response to treatment with pioglitazone in patients with type 2 diabetes mellitus

  2011cites this paper
• Pharmacogenetics of oral antidiabetic treatment.

  2011cites this paper
• PPARγ2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies.

  2011cites this paper
• Pharmacogenetics Fordiabetes Mellitus

  2011cites this paper
• Therapy with oral antidiabetic drugs: applied pharmacogenetics

  2011cites this paper
• Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.

  2011cites this paper
• Type 1 Diabetes - Complications, Pathogenesis, and Alternative Treatments

  2011cites this paper
• Pharmacogenetics in type 2 diabetes: potential implications for clinical practice

  2011cites this paper
• Pharmacogenetics for T2DM and Anti-Diabetic Drugs

  2011cites this paper
• Peroxisome proliferators-activated receptor γ2 Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients

  2011cites this paper
• Diabetes Type 1 and 2: What is Behind a Classification?

  2011cites this paper
• Polymorphism of peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes.

  2011cites this paper
• Genetic variants affecting incretin sensitivity and incretin secretion

  2010cites this paper
• The genetics of type 2 diabetes: what have we learned from GWAS?

  2010cites this paper
• PPAR transcriptional activator complex polymorphisms and the promise of individualized therapy for heart failure

  2010cites this paper
• Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus.

  2010cites this paper
• Effects of the Peroxisome Proliferator Activated Receptor‐γ Coactivator‐1α (PGC‐1α) Thr394Thr and Gly482Ser Polymorphisms on Rosiglitazone Response in Chinese Patients With Type 2 Diabetes Mellitus

  2010cites this paper
• Genetic markers in diabetes mellitus: the need and promise for specific drug therapies in defined subtypes of diabetes patients

  2010cites this paper
• Personalized pharmacotherapy for Type 2 diabetes mellitus.

  2009cites this paper
• Genetic Variation of PPARs

  2009cites this paper
• PPARγ2Pro12Ala Polymorphism and Human Health

  2009cites this paper
• Clinical translation of genetic predictors for type 2 diabetes

  2009cites this paper
• Retinoid X receptor heterodimer variants and cardiovascular risk factors.

  2009cites this paper
• Genetic Susceptibility to Type 2 Diabetes and Implications for Therapy

  2009cites this paper
• Pharmacogenetics in diabetes

  2009cites this paper
• The Genetic Basis of Diabetes

  2009cites this paper
• Personalized pharmacotherapy for Type 2

  2009cites this paper
• Genetic Architecture of Type 2 Diabetes: Recent Progress and Clinical Implications

  2009cites this paper